CSF markers for incipient Alzheimer's disease.

By Kaj Blennow, Harald Hampel. Lancet Neurology, 2003

1,293 citations recorded by the source corpus.

Subfields: Pharmacology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/70c531b20f8f4b190cca9c897cbba6e788f5032c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Mild cognitive impairment (2006, background): “These proteins are thought to reflect the neurodegeneration caused by AD (Blennow and Hampel, 2003).”
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers (2016, background): “Taken together, these data indicate that CSF t-tau reflects the intensity of neuronal degeneration in AD at a specific point, while p-tau seems more specific for the burden of AD-type tau pathology accumulated over time.(42) Tau PET is being actively investigated, but initial data indicate that tau ”
Random forest-based similarity measures for multi-modal classification of Alzheimer's disease (2013, neutral): “For example, reduced CSF Aβ and elevated CSF tau are also associated with Lewy body dementia and vascular dementia (Andreasen et al., 2001; Blennow and Hampel, 2003).”
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (2010, neutral): “Biomarkers can be compounds obtained from bodily fluids or tissue, such as cerebrospinal fluid (CSF) assay”
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, neutral): “It is important to note some differences among biomarkers in the (N) group [114].”
Biomarkers for Alzheimer's disease: current status and prospects for the future (2018, background): “CSF T-tau has been proposed as a “state marker”, reflecting the intensity of neurodegeneration or severity of acute neuronal damage (55).”
Cerebrospinal Fluid Biomarker Signature in Alzheimer’s Disease Neuroimaging Initiative Subjects (2009, background): “Ann Neurol 2009;65:403–413 If the clinical diagnosis of probable AD is imprecise with accuracy rates of approximately 90% or lower using established consensus criteria for probable AD, but definite AD requires autopsy confirmation, it is not surprising that diagnostic accuracy is lower at early and ”
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, methodology): “…181 and 231) in combination with reduced levels of soluble Ab1-42 amyloid distinguish AD patients from controls based on imaging tests (Shaw et al. 2009) and correlate with the presence of AD pathology at autopsy (Tapiola et al. 2009; reviewed in Blennow and Hampel 2003; Blennow et al. 2010).”
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. (2006, methodology): “CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease Katharina Buerger,1,* Michael Ewers,1,* Tuula Pirttilä,2 Raymond Zinkowski,4 Irina Alafuzoff,3 Stefan J. Teipel,1 John DeBernardis,4 Daniel Kerkman,4 Cheryl McCulloch,4 Hilkka Soininen2 and H”
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. (2009, methodology): “A 142 levels were determined using a sandwich ELISA (Innotest -amyloid[1-42]), specifically constructed to measure A containing both the 1st and 42nd amino acids, as previously described.”
Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease (2010, background): “In addition to cerebrospinal ﬂ uid derived biomarkers (Blennow and Hampel, 2003; Ewers et al., 2007; Hansson et al., 2006; Herukka et al., 2007; Zhong et al., 2007), neuroimaging markers have been recommended to be included in the revised NINCDS-ADRDA diagnostic…”